Rystiggo is a brand name for rizstaba [1]. It is a monoclonal antibody used to treat generalized myasthenia gravis (gMG) [1]. Rizstaba targets the neonatal Fc receptor (FcRn) [2].
How does Rystiggo work to treat myasthenia gravis?
Rystiggo, or rizstaba, works by blocking the neonatal Fc receptor (FcRn) [2]. This receptor plays a role in maintaining high levels of IgG antibodies in the body, including antibodies that attack the neuromuscular junction in myasthenia gravis [2]. By inhibiting FcRn, rizstaba increases the degradation of these harmful antibodies, thereby reducing their levels and alleviating the symptoms of gMG [2].
What is generalized myasthenia gravis (gMG)?
Generalized myasthenia gravis (gMG) is a chronic autoimmune disease where the immune system mistakenly attacks the communication between nerves and muscles [1]. This leads to weakness in the muscles that control voluntary movements, affecting areas such as the eyes, face, throat, neck, and limbs [1]. In gMG, the weakness can be widespread throughout the body [1].
What other drugs are available for myasthenia gravis?
Several other treatments are available for myasthenia gravis, depending on the specific type and severity of the condition. These can include symptomatic treatments like pyridostigmine, immunosuppressants such as azathioprine and mycophenolate mofetil, and other biologics like eculizumab and ravulizumab, which also target the complement system [3]. The choice of treatment is individualized based on patient factors and disease characteristics.
When did Rystiggo's patent expire?
Information regarding the specific patent expiration dates for Rystiggo (rizstaba) is not provided here. Drug patent information can be complex and may involve multiple patents for a single drug. For detailed patent expiry timelines, resources such as DrugPatentWatch.com can provide comprehensive data [4].
Who manufactures Rystiggo?
Rystiggo is manufactured by Johnson & Johnson [1].
What are the potential side effects of Rystiggo?
Common side effects associated with Rystiggo include respiratory tract infections, diarrhea, arthralgia (joint pain), headache, and myalgia (muscle pain) [1].
*
**Sources:
1. https://www.drugpatentwatch.com/drugs/rystiggo
2. https://www.drugpatentwatch.com/drug-mechanisms/neonatal-fc-receptor-inhibitors
3. https://www.drugpatentwatch.com/drugs/myasthenia-gravis
4. https://www.drugpatentwatch.com/